

# ARMY RDT&E BUDGET ITEM JUSTIFICATION (R2 Exhibit)

February 2006

## BUDGET ACTIVITY

## PE NUMBER AND TITLE

**4 - Advanced Component Development and Prototypes**

**0603807A - Medical Systems - Adv Dev**

	COST (In Thousands)	FY 2005 Estimate	FY 2006 Estimate	FY 2007 Estimate	FY 2008 Estimate	FY 2009 Estimate	FY 2010 Estimate	FY 2011 Estimate	Cost to Complete	Total Cost
	Total Program Element (PE) Cost	20277	23149	11973	13160	22085	21287	10870	0	146448
808	DOD DRUG & VACC AD	5251	6253	5490	6309	5915	5718	5627	0	50654
811	MIL HIV VAC&DRUG DEV	0	144	149	151	150	142	141	0	1005
836	COMBAT MEDICAL MATL AD	7322	5612	3814	4784	14200	13729	3411	0	60661
837	SOLDIER SYS PROT-AD	712	938	2520	1916	1820	1698	1691	0	13207
A01	COMBAT SUPPORT HOSPITAL - MOBILE SURGICAL UNIT	0	4041	0	0	0	0	0	0	6429
MD4	FUTURE MEDICAL SHELTER	5078	5175	0	0	0	0	0	0	11592
MD8	ELECTROSOMOTIC PAIN THERAPY SYSTEM (CA)	957	986	0	0	0	0	0	0	1943
MD9	PORTABLE OXYGEN GENERATOR (CA)	957	0	0	0	0	0	0	0	957

**A. Mission Description and Budget Item Justification:** This program element (PE) funds advanced development of medical materiel within the early system integration portion of the System Development and Demonstration phase of the acquisition life cycle. The PE supports transition of Science and Technology initiatives, prototypes, or candidate technologies into the first scale-up, integrated models for initial technical and operational test and evaluation, when applicable. These programs are aligned to meet Future Force (F2) requirements stressed within the concept documents and organizational structures. The PE provides funding for early Phase 1 and 2, U.S. Food and Drug Administration (FDA) regulated, human clinical trials. The major enablers supported by this PE are:

Infectious disease vaccines and preventive drugs that will reduce the risk of service members contracting debilitating or fatal diseases, an increasing risk with the growing potential for urban warfare and its associated disease hazards. Disease and non-battle injuries (DNBI) are the largest contributors to the level 3 medical footprint, and significant reductions of the medical footprint in theater is achieved by reducing the number of DNBI affected soldiers. More importantly, reduced patient evacuations within F2 units is a force multiplier, because timely replacement of these uniquely skilled and combat tested soldiers will be nearly impossible.

Combat Casualty Care devices and biologics, with two major focuses: enhance forward care at the first responder level and reduce the footprint of medical organizations for greater mobility and easier sustainment. The F2 concept places soldiers into a more austere environment with lengthened evacuation times (both arrival and transit). Supporting medics and first responders require greater lifesaving and extended stabilization capability to save lives. Reduction in weight, cube, and sustainment requirements, allows medical units to increase mobility and maintain contact with their supported Units of Action.

Soldier Performance Enhancers in the form of drugs or diagnostics that allow commanders to increase soldiers' cognitive awareness and stamina. Enhancers have a direct relationship to increased soldier capabilities and a potential to reduce casualties.

Military Human Immunodeficiency Virus (HIV) Vaccine and Drug Development - funds militarily relevant HIV medical countermeasures. These include advanced component

ARMY RDT&E BUDGET ITEM JUSTIFICATION (R2 Exhibit)		February 2006
BUDGET ACTIVITY 4 - Advanced Component Development and Prototypes	PE NUMBER AND TITLE 0603807A - Medical Systems - Adv Dev	
development of multiple candidate vaccines and drugs for large-scale field testing.		
This program is managed by the U.S. Army Medical Research and Materiel Command.		

ARMY RDT&E BUDGET ITEM JUSTIFICATION (R2 Exhibit)				February 2006
BUDGET ACTIVITY <b>4 - Advanced Component Development and Prototypes</b>		PE NUMBER AND TITLE <b>0603807A - Medical Systems - Adv Dev</b>		
	FY 2005	FY 2006	FY 2007	
<b><u>B. Program Change Summary</u></b>				
Previous President's Budget (FY 2006)	20286	10134	11842	
Current BES/President's Budget (FY 2007)	20277	23149	11973	
Total Adjustments	-9	13015	131	
Congressional Program Reductions		-102		
Congressional Rescissions		-233		
Congressional Increases		13350		
Reprogrammings	-9			
SBIR/STTR Transfer				
Adjustments to Budget Years			131	
FY2006 - Congressional Plus-Up (\$13,350) - Electro-osmotic Pain Therapy System for Adjustable Rate Implanatable Drug Delivery (\$1,000); Leishmania Diagnostic Test (\$1,000); Lightweight Trauma Module (\$1,000); Non-Invasive Medical Sensors - Enhanced (\$1,000); Combat Support Hospital - Mobile Surgical Unit (\$4,100); Future Medical Shelter System - 21st Century Military Hospital System (\$5,250).				

ARMY RDT&E BUDGET ITEM JUSTIFICATION (R2a Exhibit)								February 2006	
BUDGET ACTIVITY <b>4 - Advanced Component Development and Prototypes</b>				PE NUMBER AND TITLE <b>0603807A - Medical Systems - Adv Dev</b>				PROJECT <b>808</b>	
COST (In Thousands)	FY 2005 Estimate	FY 2006 Estimate	FY 2007 Estimate	FY 2008 Estimate	FY 2009 Estimate	FY 2010 Estimate	FY 2011 Estimate	Cost to Complete	Total Cost
808 DOD DRUG & VACC AD	5251	6253	5490	6309	5915	5718	5627	0	50654
<b>A. Mission Description and Budget Item Justification:</b> This project funds technical development of candidate medical countermeasures for infectious diseases that occur within militarily relevant areas of the world. Current products fall within three major areas: vaccines, drugs, and diagnostic kits. The funds support Phase 1 and 2 human clinical trials for safety and small-scale efficacy testing. This work, which is performed in military laboratories or civilian pharmaceutical firms, is directed toward the prevention of disease, early diagnosis if contracted, and speeding recovery once diagnosed. These trials are required to meet U.S. Food and Drug Administration (FDA) regulatory approval guidance, a mandatory obligation for all military products placed into the hands of medical providers or service members. Priority is based upon four major factors: (1) the extent of the disease within the Combatant Commands' theater of operations, (2) the clinical severity of the disease, (3) the technical maturity of the proposed solution, and (4) the affordability of the solution (development and production).									
<b>Accomplishments/Planned Program</b>						<u>FY 2005</u>	<u>FY 2006</u>	<u>FY 2007</u>	
Reviews, evaluations, and trials of malarial/anti-malarial vaccines, drugs, and diagnostics: In FY05, began an FDA mandated Phase 3 Malaria Rapid Diagnostic Device (MRDD) clinical trial in the United States. Initiated a Phase 1/2 trial of the Recombinant Plasmodium falciparum Malaria Vaccine plus Adjuvant (RTS,S) in Kenya. In FY06 complete MRDD Phase 3 clinical trial and conduct a Milestone C IPR to transition MRDD to Full-Rate Production and Deployment, resulting in fielding of state-of-the-art malaria diagnostic capability for military physicians. Conduct a Critical Design Review (CDR) to determine if the Recombinant Plasmodium falciparum Malaria Vaccine plus Adjuvant (RTS,S) should continue as a single vaccine or be de-transitioned to Technology Development for testing with other Malaria vaccine candidates. In FY07, transition the anti-malarial drug, Artesunate (for intravenous treatment of severe and complicated malaria) to System Development and Demonstration (Milestone B) and initiate Phase 2b efficacy studies.						2596	3243	4000	
Trials, evaluations, and reviews for grouped infectious disease vaccines and drugs (Dengue and Leishmania): In FY05, completed Phase 2 testing of the Dengue Tetravalent Vaccine (DTV) in Thailand and initiated analysis of results. Completed analysis of the data from a Phase 2 field trial of the current formulation of the Paromomycin/Gentamicin Topical Antileishmanial Cream. Awarded a contract for the production of a formulation of the Antileishmanial Topical for pivotal field testing and licensure. In FY06, conduct a Critical Design Review and initiate Phase 2b efficacy studies of the DTV; conduct a Critical Design Review and initiate pivotal field trials of the Paromomycin/Gentamicin Topical Antileishmanial Cream. In FY07, continue field trials of both the Antileishmanial Topical and the DTV.						2655	3010	1490	
Total						5251	6253	5490	
<b>C. Acquisition Strategy</b> Test and evaluate in-house and commercially developed products in extensive government-managed clinical trials to gather data required for FDA licensure and Environmental Protection Agency registration.									

ARMY RDT&E COST ANALYSIS (R3)										February 2006		
BUDGET ACTIVITY				PE NUMBER AND TITLE							PROJECT	
<b>4 - Advanced Component Development and Prototypes</b>				<b>0603807A - Medical Systems - Adv Dev</b>							<b>808</b>	
I. Product Development	Contract Method & Type	Performing Activity & Location	Total PYs Cost	FY 2005 Cost	FY 2005 Award Date	FY 2006 Cost	FY 2006 Award Date	FY 2007 Cost	FY 2007 Award Date	Cost To Complete	Total Cost	Target Value of Contract
No product/contract costs greater than \$1M individually			3850	471		480		486		Continue	0	Continue
Subtotal:			3850	471		480		486		Continue	0	Continue
II. Support Costs	Contract Method & Type	Performing Activity & Location	Total PYs Cost	FY 2005 Cost	FY 2005 Award Date	FY 2006 Cost	FY 2006 Award Date	FY 2007 Cost	FY 2007 Award Date	Cost To Complete	Total Cost	Target Value of Contract
No product/contract costs greater than \$1M individually			698	158		270		162		Continue	1131	Continue
Subtotal:			698	158		270		162		Continue	1131	Continue
III. Test And Evaluation	Contract Method & Type	Performing Activity & Location	Total PYs Cost	FY 2005 Cost	FY 2005 Award Date	FY 2006 Cost	FY 2006 Award Date	FY 2007 Cost	FY 2007 Award Date	Cost To Complete	Total Cost	Target Value of Contract
No product/contract costs greater than \$1M individually			17120	3782		4349		3892		Continue	25395	Continue
Subtotal:			17120	3782		4349		3892		Continue	25395	Continue
IV. Management Services	Contract Method & Type	Performing Activity & Location	Total PYs Cost	FY 2005 Cost	FY 2005 Award Date	FY 2006 Cost	FY 2006 Award Date	FY 2007 Cost	FY 2007 Award Date	Cost To Complete	Total Cost	Target Value of Contract
No product/contract costs greater than \$1M individually			3710	840		1154		950		Continue	5820	0
Subtotal:			3710	840		1154		950		Continue	5820	0

ARMY RDT&E COST ANALYSIS (R3)							February 2006				
BUDGET ACTIVITY			PE NUMBER AND TITLE						PROJECT		
4 - Advanced Component Development and Prototypes			0603807A - Medical Systems - Adv Dev						808		
Project Total Cost:			25378	5251		6253		5490	Continue	32346	0

Schedule Profile (R4 Exhibit)																		February 2006																	
BUDGET ACTIVITY								PE NUMBER AND TITLE																		PROJECT									
4 - Advanced Component Development and Prototypes								0603807A - Medical Systems - Adv Dev																		808									
Event Name								FY 05				FY 06				FY 07				FY 08				FY 09				FY 10				FY 11			
								1	2	3	4	1	2	3	4	1	2	3	4	1	2	3	4	1	2	3	4	1	2	3	4	1	2	3	4
(1) Dengue Tetravalent Vaccine								Critical Design Review				▲1																							
(2) Antimalarial, Artesunate												MS B				▲2																			
(3) RTS, S Improved Adjuvant Malaria Vaccine								Critical Design Review				▲3																							
(4) Malaria Rapid Diag Device								MS C				▲4																							
(5) Paromomycin/Gent, (6) Paromomycin/Gent								Critical Design Review				▲5								MS C				▲6											








Schedule Detail (R4a Exhibit)						February 2006	
BUDGET ACTIVITY <b>4 - Advanced Component Development and Prototypes</b>			PE NUMBER AND TITLE <b>0603807A - Medical Systems - Adv Dev</b>			PROJECT <b>808</b>	
<u>Schedule Detail</u>	<u>FY 2005</u>	<u>FY 2006</u>	<u>FY 2007</u>	<u>FY 2008</u>	<u>FY 2009</u>	<u>FY 2010</u>	<u>FY 2011</u>
Paromomycin/Gentamicin (Critical Design Review) (MS C)		1Q			2Q		
RTS,S/Improved Adjuvant (P. falciparum) Malaria Vaccine (Critical Design Review)		2Q					
Malaria Rapid Diagnostic Device (MS C)		1Q					
Dengue Tetravalent Vaccine (Critical Design Review)		1Q					
Antimalarial, Artesunate (MS B)			1Q				



ARMY RDT&E BUDGET ITEM JUSTIFICATION (R2a Exhibit)								February 2006	
BUDGET ACTIVITY <b>4 - Advanced Component Development and Prototypes</b>				PE NUMBER AND TITLE <b>0603807A - Medical Systems - Adv Dev</b>				PROJECT <b>836</b>	
COST (In Thousands)	FY 2005 Estimate	FY 2006 Estimate	FY 2007 Estimate	FY 2008 Estimate	FY 2009 Estimate	FY 2010 Estimate	FY 2011 Estimate	Cost to Complete	Total Cost
836 COMBAT MEDICAL MATL AD	7322	5612	3814	4784	14200	13729	3411	0	60661
<b>A. Mission Description and Budget Item Justification:</b> This project funds technical development of candidate medical products for the advancement of combat casualty care; especially far forward on the battlefield for first responders, combat life savers, and field medics. This funds Phase 1 and 2 human clinical trials for safety and efficacy of devices unique to military operational requirements. These products will decrease mortality rates increase soldiers' morale and willingness to place themselves in danger. Additionally, several products will reduce the medical organizational sustainment footprint through smaller the weight and cube and equipment independence from supporting materials. Priority is given to those products that provide the greatest clinical benefit balanced with the technical and financial risks.									
<b>Accomplishments/Planned Program</b>						<u>FY 2005</u>	<u>FY 2006</u>	<u>FY 2007</u>	
(1) Hemostatic Dressing (HD): In FY05, established contract with new subject matter expert of fibrin hemostat technologies and identified HD manufacturing equipment requirements. Began business case analysis to determine affordability, manufacturability, and commerciality of current and emerging fibrin hemostat technologies. In FY06, complete report on affordability, manufacturability, and commerciality of current and emerging fibrin hemostat technologies. (2) Chitosan Control Dressing (CCD): In FY05, continued work on development of long-term internal use dressing. Began development of new antimicrobial chitosan burn dressing.						428	250	0	
Conduct/Perform development, testing and Milestone reviews for field medical treatment and treatment aid devices:(1)Ceramic Oxygen Generator (COG):In FY05, fabricated first portable oxygen generator prototype. In FY06, conduct user and technical testing. Conduct Milestone B. In FY07, develop engineering pre-production prototype and obtain FDA clearance. (2)Ventilatory Assist Device (VAD):In FY05, conducted technical and user testing, and made required modifications. Held Milestone C review. Supported the fielding process.(3)One-Handed Tourniquet (OHT):In FY05, completed project. (4)Non-Contact Respiration Monitor (NCRM):In FY05, completed prototype, conducted user evaluation and determined that product is not a requirement at this time. (5)Rotary Valve Pressure Swing Adsorption Oxygen Generator (RVPSAOG):In FY05, reduced oxygen generator weight and size. Found potentially more reliable air compressor. In FY06, Conduct Milestone B review. Develop engineering pre-production prototype. Conduct technical and user testing and evaluation. In FY07, conduct Milestone C review. Initiate low rate production. (6)Battery Powered IV Fluid Warmer: In FY05, delivered prototype units for test evaluations. In FY06 first quarter, completed technical testing. FDA testing to commence at WRAIR. Begin user evaluation. Conduct Milestone B. (7)Future Medical Shelter System (FMSS):In FY05, performed test and evaluation on future medical shelter system. Began working on 2nd Generation concept based on test results. Completed phase 1 for the concept of the Operating Room Module. (8)Future Combat System (FCS):In FY05, continued work in the System Design and Development phase. In FY06, begin preparing the System Functional Review. Requirements were finalized for the Medical Vehicle and a brass board litter system was constructed. (9)Electroosmotic Pain Therapy System (EPTS):In FY05, fabricated prototype units. Obtained animal use approval. In FY06, initiate FDA requirement testing.						6894	5362	3814	
Total						7322	5612	3814	
<b>C. Acquisition Strategy</b> Evaluate commercially developed materiel in government-managed tests for hardening or other modification.									

ARMY RDT&E BUDGET ITEM JUSTIFICATION (R2a Exhibit)		February 2006
BUDGET ACTIVITY	PE NUMBER AND TITLE	PROJECT
4 - Advanced Component Development and Prototypes	0603807A - Medical Systems - Adv Dev	836

ARMY RDT&E COST ANALYSIS (R3)										February 2006		
BUDGET ACTIVITY <b>4 - Advanced Component Development and Prototypes</b>				PE NUMBER AND TITLE <b>0603807A - Medical Systems - Adv Dev</b>						PROJECT <b>836</b>		
I. Product Development	Contract Method & Type	Performing Activity & Location	Total PYs Cost	FY 2005 Cost	FY 2005 Award Date	FY 2006 Cost	FY 2006 Award Date	FY 2007 Cost	FY 2007 Award Date	Cost To Complete	Total Cost	Target Value of Contract
No other contract exceeds \$1M			11824	0		1918		61		0	13803	0
Subtotal:			11824	0		1918		61		0	13803	0
II. Support Costs	Contract Method & Type	Performing Activity & Location	Total PYs Cost	FY 2005 Cost	FY 2005 Award Date	FY 2006 Cost	FY 2006 Award Date	FY 2007 Cost	FY 2007 Award Date	Cost To Complete	Total Cost	Target Value of Contract
Subtotal:			0									
Remarks: No product/contract costs greater than \$1M individually.												
III. Test And Evaluation	Contract Method & Type	Performing Activity & Location	Total PYs Cost	FY 2005 Cost	FY 2005 Award Date	FY 2006 Cost	FY 2006 Award Date	FY 2007 Cost	FY 2007 Award Date	Cost To Complete	Total Cost	Target Value of Contract
Subtotal:			0									
Remarks: No product/contract costs greater than \$1M individually.												
IV. Management Services	Contract Method & Type	Performing Activity & Location	Total PYs Cost	FY 2005 Cost	FY 2005 Award Date	FY 2006 Cost	FY 2006 Award Date	FY 2007 Cost	FY 2007 Award Date	Cost To Complete	Total Cost	Target Value of Contract
No product/contract costs greater than \$M individually.			10660	7322		3694		3753		0	0	0
Subtotal:			10660	7322		3694		3753		0	0	0
<b>Project Total Cost:</b>			<b>22484</b>	<b>7322</b>		<b>5612</b>		<b>3814</b>		<b>0</b>	<b>13803</b>	<b>0</b>

Schedule Profile (R4 Exhibit)																	February 2006															
BUDGET ACTIVITY					PE NUMBER AND TITLE																				PROJECT							
4 - Advanced Component Development and Prototypes					0603807A - Medical Systems - Adv Dev																				836							
Event Name					FY 05				FY 06				FY 07				FY 08				FY 09				FY 10				FY 11			
					1	2	3	4	1	2	3	4	1	2	3	4	1	2	3	4	1	2	3	4	1	2	3	4	1	2	3	4
(1) Ceramic Oxygen Gen, (2) Ceramic Oxygen Gen									MS B 				MS C 																			
(3) Ventalitory Assist Device																																
(4) One-handed Tourniquet																																
(5) Rotary Valve Pressure Oxy Gen, (6) Rotary Valve Pressure OxyGene									MS B 				MS C 																			
(7) Battery-powered IV Fluid Warmer, (8) Battery-powered IV Fluid Warmer									MS B 				MS C 																			

Schedule Detail (R4a Exhibit)						February 2006	
BUDGET ACTIVITY <b>4 - Advanced Component Development and Prototypes</b>			PE NUMBER AND TITLE <b>0603807A - Medical Systems - Adv Dev</b>			PROJECT <b>836</b>	
<u>Schedule Detail</u>	<u>FY 2005</u>	<u>FY 2006</u>	<u>FY 2007</u>	<u>FY 2008</u>	<u>FY 2009</u>	<u>FY 2010</u>	<u>FY 2011</u>
Ceramic Oxygen Generator Systems (MS B, MS C)		3Q	4Q				
Ventilatory Assist Device (MS C)	2Q						
One-Handed Tourniquet (MS, C)	3Q						
Rotary Valve Pressure Swing Oxygen Generator (MSB, MS C)		3Q	4Q				
Battery-powered IV Fluid Warmer (MS B, MS C)		3Q	3Q				

<b>ARMY RDT&amp;E BUDGET ITEM JUSTIFICATION (R2a Exhibit)</b>								<b>February 2006</b>	
<b>BUDGET ACTIVITY</b> <b>4 - Advanced Component Development and Prototypes</b>				<b>PE NUMBER AND TITLE</b> <b>0603807A - Medical Systems - Adv Dev</b>				<b>PROJECT</b> <b>837</b>	
COST (In Thousands)	FY 2005 Estimate	FY 2006 Estimate	FY 2007 Estimate	FY 2008 Estimate	FY 2009 Estimate	FY 2010 Estimate	FY 2011 Estimate	Cost to Complete	Total Cost
837      SOLDIER SYS PROT-AD	712	938	2520	1916	1820	1698	1691	0	13207
<b><u>A. Mission Description and Budget Item Justification:</u></b> This project supports the conceptual and technical development of preventive medicine materiel including devices and medicines in order to provide protection, sustainment, and enhancement of the physical and psychological capabilities of soldiers across all conditions of combat. Focus is on the reduction of personnel losses due to preventable disease and non-battle injuries through the development of environmental and physiological performance monitors and other preventive medicine countermeasures.									
<b><u>Accomplishments/Planned Program</u></b>						<b><u>FY 2005</u></b>	<b><u>FY 2006</u></b>	<b><u>FY 2007</u></b>	
In FY05, began termination phase of contract for Leishmania skin tests: In FY06, conduct a Design Readiness Review and close out Leishmania skin test contract.						442	438	0	
Provide funding for the Air Worthiness Certification of the Special Medical Emergency Evacuation Device (SMEED) and Life Support for Trauma and Transport (LSTAT) Next Generation.						270	500	2520	
Total						712	938	2520	
<b><u>C. Acquisition Strategy</u></b> Test and evaluate materiel in government-managed trials to meet fielding requirements.									

ARMY RDT&E COST ANALYSIS (R3)										February 2006		
BUDGET ACTIVITY			PE NUMBER AND TITLE								PROJECT	
<b>4 - Advanced Component Development and Prototypes</b>			<b>0603807A - Medical Systems - Adv Dev</b>								<b>837</b>	
I. Product Development	Contract Method & Type	Performing Activity & Location	Total PYs Cost	FY 2005 Cost	FY 2005 Award Date	FY 2006 Cost	FY 2006 Award Date	FY 2007 Cost	FY 2007 Award Date	Cost To Complete	Total Cost	Target Value of Contract
No product/contract costs greater than \$1M individually			1447	342		458		1203		Continue	2939	0
Subtotal:			1447	342		458		1203		Continue	2939	0
II. Support Costs	Contract Method & Type	Performing Activity & Location	Total PYs Cost	FY 2005 Cost	FY 2005 Award Date	FY 2006 Cost	FY 2006 Award Date	FY 2007 Cost	FY 2007 Award Date	Cost To Complete	Total Cost	Target Value of Contract
No product/contract costs greater than \$1M individually			79	23		35		75		Continue	178	0
Subtotal:			79	23		35		75		Continue	178	0
III. Test And Evaluation	Contract Method & Type	Performing Activity & Location	Total PYs Cost	FY 2005 Cost	FY 2005 Award Date	FY 2006 Cost	FY 2006 Award Date	FY 2007 Cost	FY 2007 Award Date	Cost To Complete	Total Cost	Target Value of Contract
No product/contract costs greater than \$1M individually		Research and development; stability and potency testing	356	127		160		456		Continue	907	0
Subtotal:			356	127		160		456		Continue	907	0
IV. Management Services	Contract Method & Type	Performing Activity & Location	Total PYs Cost	FY 2005 Cost	FY 2005 Award Date	FY 2006 Cost	FY 2006 Award Date	FY 2007 Cost	FY 2007 Award Date	Cost To Complete	Total Cost	Target Value of Contract
No product/contract costs greater than \$1M individually			885	220		285		786		Continue	1850	0
Subtotal:			885	220		285		786		Continue	1850	0

ARMY RDT&E COST ANALYSIS (R3)							February 2006				
BUDGET ACTIVITY		PE NUMBER AND TITLE							PROJECT		
4 - Advanced Component Development and Prototypes		0603807A - Medical Systems - Adv Dev							837		
Project Total Cost:		2767	712		938		2520		Continue	5874	0



Schedule Profile (R4 Exhibit)																		February 2006																																																																																																																																																																																																																																																																																																																																																																																													
BUDGET ACTIVITY								PE NUMBER AND TITLE																				PROJECT																																																																																																																																																																																																																																																																																																																																																																																			
4 - Advanced Component Development and Prototypes								0603807A - Medical Systems - Adv Dev																				837																																																																																																																																																																																																																																																																																																																																																																																			
Event Name								FY 05				FY 06				FY 07				FY 08				FY 09				FY 10				FY 11																																																																																																																																																																																																																																																																																																																																																																															
								1	2	3	4	1	2	3	4	1	2	3	4	1	2	3	4	1	2	3	4	1	2	3	4	1	2	3	4																																																																																																																																																																																																																																																																																																																																																																												
(1) Leishmania Skin Test								Design Readiness Review																																																																																																																																																																																																																																																																																																																																																																																																							

Schedule Detail (R4a Exhibit)						February 2006	
BUDGET ACTIVITY 4 - Advanced Component Development and Prototypes			PE NUMBER AND TITLE 0603807A - Medical Systems - Adv Dev			PROJECT 837	
<u>Schedule Detail</u>	<u>FY 2005</u>	<u>FY 2006</u>	<u>FY 2007</u>	<u>FY 2008</u>	<u>FY 2009</u>	<u>FY 2010</u>	<u>FY 2011</u>
Leishmania Skin Test		3Q					